{
    "id": 5161,
    "fullName": "VHL mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "VHL mutant indicates an unspecified mutation in the VHL gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 7428,
        "geneSymbol": "VHL",
        "terms": [
            "VHL",
            "HRCA1",
            "pVHL",
            "RCA1",
            "VHL1"
        ]
    },
    "variant": "mutant",
    "createDate": "04/22/2015",
    "updateDate": "10/11/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2280,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I study, Afinitor (everolimus), as compared to Apitolisib (GDC-0980), resulted in a greater progression free survival and overall survival in patients with renal cell carcinoma harboring VHL mutations (J Clin Oncol 32:5s, 2014 (suppl; abstr 4525)).",
            "molecularProfile": {
                "id": 4973,
                "profileName": "VHL mutant"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2962,
                    "pubMedId": null,
                    "title": "A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT)",
                    "url": "http://meetinglibrary.asco.org/content/132562-144"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2271,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, 33% (6/18) of renal cell carcinoma patients harboring a VHL mutation, as determined from archived patient specimens, demonstrated a partial response when treated with Sutent (sunitinib) (PMID: 22105611).",
            "molecularProfile": {
                "id": 4973,
                "profileName": "VHL mutant"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 2901,
                    "pubMedId": 22105611,
                    "title": "Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22105611"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12599,
            "approvalStatus": "Clinical Study - Meta-analysis",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a meta-analysis of 6 clinical studies, VHL mutation status was not associated with overall response rate (relative risk=1.47, p=0.20), progression-free survival (HR=1.02, p=0.91), or overall survival (HR=0.80, p=0.21) in a total of 633 patients with renal cell carcinoma who received anti-VEGF therapies (PMID: 28103578).",
            "molecularProfile": {
                "id": 4973,
                "profileName": "VHL mutant"
            },
            "therapy": {
                "id": 8151,
                "therapyName": "Unspecified VEGFR inhibitor",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10471,
                    "pubMedId": 28103578,
                    "title": "Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28103578"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2067,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a rapamycin-resistant human kidney cancer cell line harboring mutations in CDKN2A, SETD2 and VHL demonstrated sensitivity and inhibition of MTORC1 signaling when treated with Sapanisertib (MLN0128) (PMID: 25261369).",
            "molecularProfile": {
                "id": 4976,
                "profileName": "CDKN2A mut SETD2 mut VHL mut"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2380,
                    "pubMedId": 25261369,
                    "title": "Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25261369"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 4973,
            "profileName": "VHL mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 4976,
            "profileName": "CDKN2A mut SETD2 mut VHL mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}